Board of Directors
Tim Wilson, PhD.
Chief Executive Officer
Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including
Pete Finan
Non-Executive Chairman
Pete joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining
Marianne Uteng
Board Member
Marianne Uteng PhD is a Managing Director at NVF in Basel, Switzerland. Prior to that, she worked in Novartis Global Drug Development, and in the Pre-Clinical Safety Department
Marianne Bjørdal
Board Member
Marianne is a Partner at 3B Future Health Ventures, advisor to a venture capital fund investing in early-stage companies developing novel technologies and new treatments in oncology and
Alek Safarian
Board Member
Alek Safarian is the CEO of venture investment firm, ALSA Holdings Ltd. Alek has a diverse background in drug development spanning some 30 years. Trained as a pharmacist,
Emma Johnson
Board Member
Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on opportunities in the life sciences. Emma joined the BPC team